Analysis of Prognostic Factors of 80 Advanced NSCLC Patients Treated with Gefitinib for more than 6 Months
Background and objective Some clinical predictors can be used to evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC), including female, East-Asian, non-smoker, adenocarcinoma, skin rash, etc. The aim of this st...
Main Authors: | Ling DAI, Jian FANG, Jun NIE, Weiheng HU, Xiaoling CHEN, Jindi HAN, Guangming TIAN, Sen HAN, Xuyi LIU |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2010-11-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2010.11.10 |
Similar Items
-
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01) -
Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01) -
Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
by: Hu Y, et al.
Published: (2017-04-01) -
EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
by: Meng J, et al.
Published: (2019-07-01) -
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
by: Hongbo Zhao, et al.
Published: (2018-11-01)